MORPHIC HOLDING, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.37 USD | -1.46% |
|
-1.40% | +5.16% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 200K 15.69M | Sales 2025 * | 750K 58.85M | Capitalization | 1.52B 119B |
|---|---|---|---|---|---|
| Net income 2024 * | -199M -15.62B | Net income 2025 * | -229M -17.97B | EV / Sales 2024 * | 4,841 x |
| Net cash position 2024 * | 553M 43.4B | Net cash position 2025 * | 527M 41.37B | EV / Sales 2025 * | 1,325 x |
| P/E ratio 2024 * |
-7.6
x | P/E ratio 2025 * |
-7.04
x | Employees | 124 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.16% |
More Fundamentals
* Assessed data
More news
Latest transcript on Morphic Holding, Inc.
More recommendations
More press releases
| 1 day | -1.46% | ||
| 1 week | -1.40% | ||
| 1 month | +5.78% | ||
| 3 months | -23.17% | ||
| 6 months | +24.42% | ||
| Current year | +5.16% |
1 week
29.63
31.65
1 month
27.4733.87
Current year
26.0341.47
1 year
19.3563.08
3 years
19.2368.75
5 years
9.9093.00
10 years
9.9093.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 30/06/15 | |
Bruce Rogers
PSD | President | 55 | 31/12/15 |
Marc Schegerin
DFI | Director of Finance/CFO | 48 | 05/04/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Timothy Springer
FOU | Founder | 76 | 31/07/14 |
| Director/Board Member | 68 | 31/05/19 | |
Joseph Slattery
BRD | Director/Board Member | 59 | 30/04/19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.20% | 2 M€ | -.--% | ||
| 0.08% | 0 M€ | 0.00% | - | |
| 0.07% | 0 M€ | 0.00% | - | |
| 0.07% | 7 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/05/24 | 30.37 | -1.46% | 337,782 |
| 30/05/24 | 30.82 | +2.39% | 295,630 |
| 29/05/24 | 30.1 | -2.19% | 386,065 |
| 28/05/24 | 30.78 | -0.08% | 378,419 |
Delayed Quote Nasdaq, May 31, 2024 at 09:00 pm
More quotes
Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Companyâs Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). It has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.
Calendar
04/06/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
30.37
USD
Average target price
56
USD
Spread / Average Target
+84.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.16% | 1.52B | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B | |
| -11.83% | 10.74B |
- Stock Market
- Equities
- MORF Stock
